BRIEF published on 08/26/2024 at 16:01, 1 year 3 months ago First Berlin Equity Research réitère sa note « Acheter » pour Pharming Group NV Objectif De Prix Recherche Sur Les Actions Pharmaceutique Leniolisib Croissance Des Patients
PRESS RELEASE published on 08/26/2024 at 15:56, 1 year 3 months ago Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates recommendation on Pharming Group NV to Buy with a target price of €1.60. Q2/24 showed strong performance with revenue up 35% yoy and 33% qoq Revenue First Berlin Equity Research Buy Recommendation Q2/24 Pharming Group NV
PRESS RELEASE published on 08/09/2023 at 14:46, 2 years 3 months ago Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE published on 07/18/2023 at 11:56, 2 years 4 months ago Original-Research: Pharming (von First Berlin Equity Research GmbH): Buy
Published on 12/05/2025 at 02:35, 4 hours 59 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 34 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 29 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 34 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 34 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 4 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 44 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 9 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 19 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 20 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 34 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 34 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 49 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 49 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
